Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Effective Collaboration - Team Research for Better Returns: -- Ignore unavailable to you. Want to Upgrade?

To: The Ox who wrote (2392)	7/25/2013 2:40:01 PM
From: The Ox	Respond to of 8255

Alexion Pharmaceuticals, Inc. (NASDAQ: ALXN) reported Q2 EPS of $0.73, $0.05 better than the analyst estimate of $0.68. Revenue for the quarter came in at $370.1 million versus the consensus estimate of $364.8 million. Alexion Pharmaceuticals, Inc. sees FY2013 EPS of $2.97-$3.02, versus prior guidance of $2.87-$2.97 and the consensus of $2.96. Alexion Pharmaceuticals, Inc. sees FY2013 revenue of $1.52-1.53 billion, versus prior guidance of $1.505-1.52 billion and the consensus of $1.52 billion. “In the second quarter, we continued our strong and ongoing global performance with Soliris in PNH. In the early stages of our aHUS launch, we were especially pleased to provide Soliris to a steadily growing number of patients in the US and increasingly in Europe,” said Leonard Bell, M.D., Chief Executive Officer of Alexion. “Key pipeline initiatives, including our asfotase alfa program in HPP and our Soliris programs in NMO and transplant, reached new milestones. As we enter the second half of the year, we will continue to develop our product portfolio toward supporting an anticipated series of significant launches in new indications for Soliris and new products over the next several years."